Idiopag
Generic Name
Idiopag
Manufacturer
Fictional Pharma Inc.
Country
Hypothetical Country
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| idiopag 25 mg tablet | ৳ 600.00 | ৳ 4,200.00 |
Description
Overview of the medicine
Idiopag 25 mg Tablet is a hypothetical thrombopoietin receptor agonist indicated for the treatment of certain thrombocytopenic conditions. It works by stimulating the production of platelets in the bone marrow.
Uses & Indications
Dosage
Adults
Initial dose 25 mg orally once daily. Adjust dose based on platelet response to maintain counts ≥50 × 10^9/L. Max dose 75 mg/day.
Elderly
No specific dose adjustment is required for elderly patients based on age alone, but monitor closely for adverse effects.
Renal_impairment
No dose adjustment required for mild to moderate renal impairment. Use with caution in severe renal impairment, monitor platelet counts.
How to Take
Take orally, once daily. It is recommended to take Idiopag at least two hours before or four hours after any polyvalent cation-containing products (e.g., antacids, dairy products, and mineral supplements) to avoid reduced absorption.
Mechanism of Action
Idiopag selectively binds to and activates the thrombopoietin receptor (TPO-R) on megakaryocytes and hematopoietic stem cells, leading to increased proliferation and differentiation of megakaryocytes, and ultimately increased platelet production.
Pharmacokinetics
Onset
Platelet count increase typically observed within 1-2 weeks.
Excretion
Mainly excreted in feces (approximately 60%) and urine (approximately 30%).
Half life
Approximately 12-18 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations reached within 2-4 hours.
Metabolism
Primarily metabolized in the liver via CYP enzymes and glucuronidation.
Side Effects
Contraindications
- •Hypersensitivity to Idiopag or any components of the formulation.
- •Severe hepatic impairment (Child-Pugh Class C).
Drug Interactions
CYP2C8 inducers
Co-administration with strong CYP2C8 inducers may decrease Idiopag exposure; dose adjustment may be necessary.
CYP2C8 inhibitors
Co-administration with strong CYP2C8 inhibitors may increase Idiopag exposure; dose adjustment may be necessary.
Polyvalent cation-containing products
Antacids, dairy products, mineral supplements (calcium, iron, magnesium, aluminum, selenium, zinc) can chelate Idiopag, reducing absorption. Administer Idiopag at least 2 hours before or 4 hours after these products.
Storage
Store at room temperature (20-25°C), away from moisture and direct light. Keep out of reach of children.
Overdose
In case of an overdose, platelet counts may increase excessively, leading to an increased risk of thrombotic complications. Management should involve close monitoring of platelet counts and supportive care. Idiopag is not extensively cleared by hemodialysis.
Pregnancy & Lactation
Idiopag should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if Idiopag is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Not commercially available
Approval Status
Hypothetical / Investigational
Patent Status
Hypothetical - Under development
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
